Maxcyte Stock Price, News & Analysis

MaxCyte celebrates its 25th anniversary as a pioneer in non-viral cell engineering technologies. The company's Flow Electroporation® technology played a important role in developing CASGEVY®, the first FDA-approved non-viral cell therapy, in collaboration with Vertex Pharmaceuticals and CRISPR Therapeutics. MaxCyte has established 29 Strategic Platform License agreements across various therapeutic areas.

In 2022, the company relocated to a 67,000 square-foot facility in Maryland's I-270 biotech corridor, expanding its manufacturing capacity and research capabilities. Under CEO Maher Masoud's leadership, MaxCyte continues to advance its proprietary ExPERT™ platform, supporting customers in developing next-generation cell therapeutics.

MaxCyte (NASDAQ: MXCT) reported Q3 2024 financial results with total revenue of $8.2 million, up 2% year-over-year. Core business revenue increased 23% to $8.1 million, driven by 39% growth in cell therapy revenue to $6.5 million. The company signed six new Strategic Platform License (SPL) partners year-to-date, bringing total SPL partners to 29. Cash position remained strong at $196.6 million. Updated 2024 guidance projects core business revenue growth of at least 5% and SPL Program-related revenue of approximately $6 million. The company is considering delisting from AIM to focus on NASDAQ listing.

MaxCyte (Nasdaq: MXCT; LSE: MXCT), a cell-engineering platform technology company, has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Stifel 2024 Healthcare Conference on November 18th at 10:55 AM ET and the Stephens Annual Investment Conference on November 19th at 3:00 PM CT. Interested parties can access live and archived webcasts of both events through MaxCyte's investor relations website.

MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) has appointed Cynthia Collins to its Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee, increasing the total Board of Directors to 10 members. With over 40 years of experience in biotechnology and cell and gene medicines, Collins brings valuable expertise to MaxCyte. Her most recent role was as CEO of Editas Medicine, where she was involved in dosing the first patient with an in-vivo gene modified therapy. Collins has also held CEO positions at Human Longevity Inc., GE Healthcare's Cell Therapy and Lab Businesses, and GenVec, Inc. She currently serves on the boards of several healthcare companies and holds a BS in Microbiology from the University of Illinois and an MBA from The University of Chicago Booth School of Business.

MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading cell-engineering focused company, has announced it will release its third quarter 2024 financial results after the U.S. market close on Wednesday, November 6th, 2024. The company, which provides enabling platform technologies for cell therapeutics and bioprocessing applications, will host a conference call to discuss the financial results at 4:30 p.m. Eastern Time on the same day.

Investors interested in participating in the earnings conference call are required to register online, with registration recommended at least a day in advance. A live and archived webcast of the event will be available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.

MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) has appointed Ali Soleymannezhad as Chief Commercial Officer, effective September 11, 2024. In his new role, Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform and expand the company's market impact in Cell and Gene Therapy. Previously, he served as Executive Vice President of Bioprocessing at MaxCyte, leading global product development and marketing strategy for the bioprocessing business.

Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to joining MaxCyte, he held executive positions at Tosoh Bioscience, including Executive Vice President for the Separations and Purification business, overseeing a team of 140 employees across four global sites. MaxCyte's CEO, Maher Masoud, expressed confidence in Soleymannezhad's ability to drive future growth for the company.

MaxCyte (Nasdaq: MXCT; LSE: MXCT) and Kamau Therapeutics have entered a strategic platform license agreement. Kamau gains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes. In return, MaxCyte will receive annual licensing fees and program-related revenue.

Kamau, a clinical-stage company, is developing gene correction therapies using homology-directed repair (HDR) editing. Their lead program, nula-cel, targets sickle cell disease (SCD). This partnership aims to optimize Kamau's clinical manufacturing process and expedite the development of potential cures for genetic diseases.

MaxCyte's ExPERT™ platform offers high transfection efficiency, scalability, and enhanced functionality for complex cell engineering. This marks MaxCyte's 29th clinical/commercial partnership, contributing to its pre-commercial milestone revenue stream.

MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering and platform technologies for cell-based therapeutics and bioprocessing applications, has announced its participation in the Virtual Craig-Hallum Capital Group Bioprocessing Conference. The event is scheduled for Thursday, September 19th at 9:30 am ET.

Company management will be presenting at the conference, providing insights into MaxCyte's innovative technologies and market position. For those unable to attend live, a replay of the event will be made available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.

This participation underscores MaxCyte's commitment to engaging with the investment community and showcasing its advancements in cell engineering and bioprocessing technologies.

MaxCyte (NASDAQ: MXCT) reported Q2 2024 financial results and updated full-year guidance. Total revenue reached $10.4 million, up 15% year-over-year. Core business revenue declined 9% to $7.6 million, while SPL Program-related revenue surged 279% to $2.9 million. The company signed five new SPL clients year-to-date, bringing the total to 28. MaxCyte affirmed its 2024 core business revenue guidance of flat to 5% growth and increased SPL Program-related revenue guidance to approximately $6 million. The company expects to end 2024 with at least $180 million in total cash, cash equivalents, and investments.